Form 4: Neurocrine Director's RSU Vesting & Tax Withholding

Neurocrine Biosciences Director Kevin Gorman reported the vesting of restricted stock units and subsequent share withholding for tax obligations.

Summary

• Director Kevin Charles Gorman of Neurocrine Biosciences Inc. (NBIX) reported a change in beneficial ownership related to the vesting of Restricted Stock Units (RSUs).
• On January 31, 2026, 5,142 shares of Common Stock were acquired by Dr. Gorman upon the vesting of RSUs, with an exercise price of $0.
• Concurrently, 2,845 shares were disposed of (withheld by the Company) to satisfy tax withholding requirements on the RSU vesting, at a price of $136.06 per share.
• No shares were sold by Dr. Gorman; the disposition was solely for tax purposes.
• Following these transactions, Dr. Gorman beneficially owns 516,893 shares of Common Stock.
• Of the beneficially owned shares, 516,893 are held indirectly by the Gorman and Blais Family Trust, where Dr. Gorman holds voting and investment power.
• The transactions were made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged schedule for the purchase or sale of equity securities.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, reflecting the routine execution of a pre-established equity compensation plan for a key director, which is generally seen as a positive for aligning management and shareholder interests.

Positives

• The vesting of Restricted Stock Units (RSUs) represents the successful execution of a long-term incentive compensation plan for a key director.
• Dr. Gorman continues to hold a significant number of shares (516,893), aligning his interests with long-term shareholder value.

Negatives

• A portion of the vested shares (2,845) was withheld by the company to cover tax obligations, resulting in a reduction of direct share holdings, though not a discretionary sale.

Future Outlook

The reported transactions are part of a pre-arranged Rule 10b5-1(c) plan, indicating a structured approach to equity compensation and insider trading compliance. The final vesting event for this specific RSU award is now complete.

Industry Context

StockSavvy.ai notes that RSU vesting and subsequent share withholding for tax purposes are standard practices for executive and director compensation in the biotechnology and pharmaceutical industries. This aligns director incentives with long-term company performance and is a common mechanism for equity-based remuneration.

Comparison to Industry Standards

• StockSavvy.ai observes that the use of restricted stock units with multi-year vesting schedules is a common compensation structure for directors and executives in publicly traded biotechnology companies, comparable to practices at firms like Amgen or Gilead Sciences.
• The withholding of shares for tax obligations upon RSU vesting is a standard, non-discretionary event, consistent with compensation practices across the broader U.S. corporate landscape.

Stakeholder Impact

• Shareholders: The transaction represents a routine compensation event for a director, with minimal direct impact on existing shareholders beyond the standard dilution associated with equity compensation plans.
• Employees: No direct impact on employees is indicated by this filing.

Key Dates

Recommendation

This Form 4 reports a routine, pre-scheduled insider transaction related to equity compensation vesting and tax withholding. It does not introduce new fundamental information or significant changes in company outlook that would warrant a change in investment recommendation. The transaction is an expected part of executive compensation.

Keywords

Neurocrine Biosciences, NBIX, Form 4, insider transaction, RSU vesting, restricted stock unit, director compensation, beneficial ownership, Kevin Gorman, tax withholding, 10b5-1 plan